Condition (MeSH)
Neurofibrosarcoma
ClinicalTrials.gov lists 97 trials for Neurofibrosarcoma or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
97 of the 97 trials are tagged with Neurofibrosarcoma itself; the rest are tagged with a narrower condition beneath it.
When did Neurofibrosarcoma trials start? (31)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 4 |
| 2024 | 5 |
| 2023 | 3 |
| 2022 | 3 |
| 2021 | 5 |
| 2020 | 5 |
| 2019 | 3 |
| 2018 | 2 |
| 2017 | 6 |
Showing 10 of 31 earlier years.
No forecast is made for this condition: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 16 trials still running at the 2026-10-09 snapshot; registered median of 46 months across 60 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Neurofibrosarcoma trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 18 |
| Phase 1/2 | 17 |
| Phase 2 | 37 |
| Phase 2/3 | 3 |
| Phase 3 | 8 |
| Not applicable | 3 |
| Observational | 10 |
| Expanded access | 1 |
How many Neurofibrosarcoma trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 18 |
| Enrolling by invitation | 2 |
| Active, not recruiting | 8 |
| Available | 1 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Neurofibrosarcoma trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | 13 |
| National Cancer Institute (NCI) | 13 |
| Children's Oncology Group | 2 |
| Novartis Pharmaceuticals | 2 |
| Tango Therapeutics, Inc. | 2 |
Which drugs are being tested for Neurofibrosarcoma? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| NIVOLUMAB | 3 |
| Imatinib | 3 |
| PEMBROLIZUMAB | 3 |
| Sirolimus | 3 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Doxorubicine | 17 |
| Ifosfamid | 12 |
| Radiation Therapy | 7 |
| Filgrastime (G-CSF) | 4 |
| Pazopanib Pill | 4 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Neurofibrosarcoma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Dyspnea | 49 | 9 |
| Pleural effusion | 46 | 9 |
| Vomiting | 45 | 10 |
| Febrile neutropenia | 38 | 5 |
| Nausea | 34 | 8 |
Showing 5 of 10 adverse events.
Which publications cover Neurofibrosarcoma? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA. | Cancer discovery | 2023 | Yes |
| Selinexor, a First in Class, Nuclear Export Inhibitor for the Treatment of Advanced Malignant Peripheral Nerve Sheath Tumor. | The oncologist | 2021 | Yes |
| A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2021 | Yes |
| The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors. | Neuro-oncology | 2018 | Yes |
| Ketamine for cancer pain. | Journal of pain and symptom management | 2000 | Yes |
Showing 5 of 7 publications.
Prevalence (4)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Malignant peripheral nerve sheath tumor | Annual incidence | 1-9 / 100 000 | Worldwide | Not stated | Exact |
| Malignant peripheral nerve sheath tumor | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Malignant peripheral nerve sheath tumor | Annual incidence | 1-9 / 100 000 | Worldwide | Not stated | Exact |
| Malignant peripheral nerve sheath tumor | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Malignant peripheral nerve sheath tumor | 3148 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Malignant peripheral nerve sheath tumor | 3148 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.